Coastal Pathology Laboratories
Services We Offer
Coastal Pathology Laboratories employs six full time cytotechnologists who examine over 35,000 Pap tests each year using the state of the art Cytyc Imager System (Hologic). Six board-certified cytopathologists are available to review the abnormal Pap tests. All Pap tests are correlated with previous Pap tests and surgical biopsies.
Coastal Pathology Laboratories also performs the Cervista HR HPV DNA and Cervista HPV 16/18 Genotyping on ThinPrep samples enabling CPL to provide the most effective and efficient technology to assist the cervical cancer screening process. Chlamydia trachomatis and Neisseria gonorrhoeae are also reflex tests performed at CPL on ThinPrep samples.
Our histotechnologists process over 25,000 specimens at Coastal Pathology Laboratories each year for the pathologists to review. The pathology staff includes multiple subspecialists; thus, CPL is able to interpret complex cases.
NATURE OF TEST: The Cervista HR HPV test utilizes DNA detection with signal amplification for identifcation of high risk Human Papilloma Virus (HPV) in specimens collected in a ThinPrep vial at a clinician's office and transported by courier to Coastal Pathology Laboratories. Tests for Chlamydia trachomatis and Neisseria gonorrhoeae may also be performed on specimens collected in a ThinPrep vial.
REFLEX TESTING FOR HPV: When requested by the patient's physician, an ASCUS-positive Pap test sample will automatically (reflexively) be tested for the presence of HPV-DNA. The benefits of reflex testing for HPV, in conjunction with a Pap test, are well established and both the American College of Obstetricians and Gynecologists (ACOG) and the American Society for Colposcopy and Cervical Pathology (ASCCP) have issued guidelines for its use. These benefits include early detection of high-grade squamous intraepithelial lesion (HSIL), immediate testing to determine the need for colposcopy, elimination of a 4-6 month follow-up delay for repeat testing, and presumed increased compliance secondary to a reduction in the number of patients lost to follow-up.